We serve Chemical Name:cymarol CAS:465-84-9 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
Chemical Name:cymarol
CAS.NO:465-84-9
Synonyms:strophandiol-d-cymarosid
Molecular Formula:C30H46O9
Molecular Weight:550.68100
HS Code:
Physical and Chemical Properties:
Melting point:240-243ºC
Boiling point:734.1ºC at 760mmHg
Density:1.32g/cm3
Index of Refraction:1.597
PSA:134.91000
Exact Mass:550.31400
LogP:2.22670
Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:
Contact us for information like strophandiol-d-cymarosid chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,strophandiol-d-cymarosid physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,strophandiol-d-cymarosid Use and application,strophandiol-d-cymarosid technical grade,usp/ep/jp grade.
Related News: The drug review center will establish a registration platform and database for APIs, pharmaceutical excipients and pharmaceutical packaging materials, which means that the domestic drug substance DMF system is expected to be gradually implemented. cymarol manufacturer At Day 35 following administration, a bone marrow assessment showed that FT819 persisted and continued to demonstrate tumor clearance, whereas primary CAR T cells, while persisting, were not able to control tumor growth. cymarol supplier The drug review center will establish a registration platform and database for APIs, pharmaceutical excipients and pharmaceutical packaging materials, which means that the domestic drug substance DMF system is expected to be gradually implemented. cymarol vendor The drug review center will establish a registration platform and database for APIs, pharmaceutical excipients and pharmaceutical packaging materials, which means that the domestic drug substance DMF system is expected to be gradually implemented. cymarol factory At Day 35 following administration, a bone marrow assessment showed that FT819 persisted and continued to demonstrate tumor clearance, whereas primary CAR T cells, while persisting, were not able to control tumor growth.
